Institution
Southeast University
Education•Nanjing, China•
About: Southeast University is a education organization based out in Nanjing, China. It is known for research contribution in the topics: Computer science & MIMO. The organization has 66363 authors who have published 79434 publications receiving 1170576 citations. The organization is also known as: SEU.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The proposed two-layer RNN model provides an effective way to make use of both spatial and temporal dependencies of the input signals for emotion recognition and experimental results demonstrate the proposed STRNN method is more competitive over those state-of-the-art methods.
Abstract: In this paper, we propose a novel deep learning framework, called spatial–temporal recurrent neural network (STRNN), to integrate the feature learning from both spatial and temporal information of signal sources into a unified spatial–temporal dependency model. In STRNN, to capture those spatially co-occurrent variations of human emotions, a multidirectional recurrent neural network (RNN) layer is employed to capture long-range contextual cues by traversing the spatial regions of each temporal slice along different directions. Then a bi-directional temporal RNN layer is further used to learn the discriminative features characterizing the temporal dependencies of the sequences, where sequences are produced from the spatial RNN layer. To further select those salient regions with more discriminative ability for emotion recognition, we impose sparse projection onto those hidden states of spatial and temporal domains to improve the model discriminant ability. Consequently, the proposed two-layer RNN model provides an effective way to make use of both spatial and temporal dependencies of the input signals for emotion recognition. Experimental results on the public emotion datasets of electroencephalogram and facial expression demonstrate the proposed STRNN method is more competitive over those state-of-the-art methods.
335 citations
••
Fudan University1, Harbin Medical University2, Chongqing Medical University3, Sichuan University4, Sun Yat-sen University5, Anhui Medical University6, Nanjing University7, Zhejiang University8, Jining Medical University9, Huazhong University of Science and Technology10, First Affiliated Hospital of Wenzhou Medical University11, Nanchang University12, Xi'an Jiaotong University13, Bengbu Medical College14, Jilin University15, Peking Union Medical College Hospital16, Southeast University17, Zhengzhou University18, Southwest General Health Center19
TL;DR: The phase 2-3 ORIENT-32 study as discussed by the authors compared sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma.
Abstract: Summary Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV) infection is the main causative factor. Patients with hepatocellular carcinoma have a poor prognosis and a substantial unmet clinical need. The phase 2–3 ORIENT-32 study aimed to assess sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma. Methods This randomised, open-label, phase 2–3 study was done at 50 clinical sites in China. Patients aged 18 years or older with histologically or cytologically diagnosed or clinically confirmed unresectable or metastatic hepatocellular carcinoma, no previous systemic treatment, and a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 were eligible for inclusion. In the phase 2 part of the study, patients received intravenous sintilimab (200 mg every 3 weeks) plus intravenous IBI305 (15 mg/kg every 3 weeks). In the phase 3 part, patients were randomly assigned (2:1) to receive either sintilimab plus IBI305 (sintilimab–bevacizumab biosimilar group) or sorafenib (400 mg orally twice daily; sorafenib group), until disease progression or unacceptable toxicity. Randomisation was done using permuted block randomisation, with a block size of six, via an interactive web response system, and stratified by macrovascular invasion or extrahepatic metastasis, baseline α-fetoprotein, and ECOG performance status. The primary endpoint of the phase 2 part of the study was safety, assessed in all patients who received at least one dose of study drug. The co-primary endpoints of the phase 3 part of the study were overall survival and independent radiological review committee (IRRC)-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in the intention-to-treat population. The study is registered with ClinicalTrials.gov , NCT03794440 . The study is closed to new participants and follow-up is ongoing for long-term outcomes. Findings Between Feb 11, 2019 and Jan 15, 2020, we enrolled 595 patients: 24 were enrolled directly into the phase 2 safety run-in and 571 were randomly assigned to sintilimab–bevacizumab biosimilar (n=380) or sorafenib (n=191). In the phase 2 part of the trial, 24 patients received at least one dose of the study drug, with an objective response rate of 25·0% (95% CI 9·8–46·7). Based on the preliminary safety and activity data of the phase 2 part, in which grade 3 or worse treatment-related adverse events occurred in seven (29%) of 24 patients, the randomised phase 3 part was started. At data cutoff (Aug 15, 2020), the median follow-up was 10·0 months (IQR 8·5–11·7) in the sintilimab–bevacizumab biosimilar group and 10·0 months (8·4–11·7) in the sorafenib group. Patients in the sintilimab–bevacizumab biosimilar group had a significantly longer IRRC-assessed median progression-free survival (4·6 months [95% CI 4·1–5·7]) than did patients in the sorafenib group (2·8 months [2·7–3·2]; stratified hazard ratio [HR] 0·56, 95% CI 0·46–0·70; p Interpretation Sintilimab plus IBI305 showed a significant overall survival and progression-free survival benefit versus sorafenib in the first-line setting for Chinese patients with unresectable, HBV-associated hepatocellular carcinoma, with an acceptable safety profile. This combination regimen could provide a novel treatment option for such patients. Funding Innovent Biologics. Translation For the Chinese translation of the abstract see Supplementary Materials section.
335 citations
••
TL;DR: This article focuses on the signal amplification strategies of AuNPs in biosensing/biorecognition, more specifically, on the main optical and electrochemical detection methods that involve AuNP-based biosensing.
335 citations
••
TL;DR: Exosomes/microvesicles secreted by iPS cells are very effective at transmitting cytoprotective signals to cardiomyocytes in the setting of MIR, and represent novel biological nanoparticles that offer the benefits of iPS cell therapy without the risk of tumorigenicity.
335 citations
••
31 Jul 2020
TL;DR: Restrictions on the use of public space and physical distancing have been key policy measures to reduce the transmission of COVID-19 and protect public health.
Abstract: Restrictions on the use of public space and physical distancing have been key policy measures to reduce the transmission of COVID-19 and protect public health. At the time of writing, one half of t...
333 citations
Authors
Showing all 66906 results
Name | H-index | Papers | Citations |
---|---|---|---|
H. S. Chen | 179 | 2401 | 178529 |
Yang Yang | 171 | 2644 | 153049 |
Gang Chen | 167 | 3372 | 149819 |
Xiang Zhang | 154 | 1733 | 117576 |
Rui Zhang | 151 | 2625 | 107917 |
Yi Yang | 143 | 2456 | 92268 |
Guanrong Chen | 141 | 1652 | 92218 |
Wei Huang | 139 | 2417 | 93522 |
Jun Chen | 136 | 1856 | 77368 |
Jian Li | 133 | 2863 | 87131 |
Xiaoou Tang | 132 | 553 | 94555 |
Zhen Li | 127 | 1712 | 71351 |
Tao Zhang | 123 | 2772 | 83866 |
Bo Wang | 119 | 2905 | 84863 |
Jinde Cao | 117 | 1430 | 57881 |